Welcome to LookChem.com Sign In|Join Free

CAS

  • or

485-35-8

Post Buying Request

485-35-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

485-35-8 Usage

Description

Different sources of media describe the Description of 485-35-8 differently. You can refer to the following data:
1. Cytisine (also known as baptitoxine and sophorine) is a kind of naturally occurring alkaloid that can be found in several plant genera including Laburnum and Cytisus in the family Fabaceae. It has been shown that it is effective in the smoking cessation treatment. It is a low efficacy partial agonist of alpha4-beta2 nicotinic acetylcholine receptors, which is the central target of the nicotine that facilitates addiction. Cytisine is capable of reducing the effect of nicotine on dopamine release on the mesolimbic system as well as attenuating the nicotine withdrawal symptoms. Cytisine is also a useful reagent for organic chemistry such as being used for the manufacture of sparteine surrogate.
2. It is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. Pi-Zhen-Ye-Huang-Hua (Thermopsis lanceolata R.Br) contains large amount of cytisine, and it is distributed in the northeast, north, and northwest of China. This herb has been traditionally used for treating cough in China and was recorded in “Yue-Wang-Yao-Zhen,”“Jing-ZhuBen-Cao,”“Zhong-Hua-Ben-Cao,” and “Ning-Xia-Zhong-Cao-Yao-Shou-Ce.”

Biological Functions

Cytisine has a physiological action similar to that of nicotine. Poisoning in Europe is generally from laburnum trees (Laburnum anagyroides, Leguminosae), while, in the tropics and America, Sophora species (Leguminosae) are often the cause. The alkaloid occurs in all parts of laburnum, but is most concentrated in the seeds, which can be mistaken for peas by children. Cytisine does not always affect cattle, but this compound can be excreted in milk and so poison children.

References

Different sources of media describe the References of 485-35-8 differently. You can refer to the following data:
1. https://en.wikipedia.org/wiki/Cytisine https://www.drugbank.ca/drugs/DB09028
2. Husemann, Marme., Z. Chem., 161 (1865) Husemann., ibid, 677 (1869) Galovinsky, Goldberger, pohm., Monatsh., 80, 550 (194

Chemical Properties

Off-White to Tan Crystalline Solid

Physical properties

Appearance: white or yellow powder. Solubility: soluble in water, pyridine, acetone, ethanol, and methanol and only slightly soluble in benzene but insoluble in petroleum ether. Melting point: 154–156?°C. Specific optical rotation: ?114.0 to ?116.0° (C?=?0.1, H2O). Toxic, stable under room temperature, and should be kept in a dry and dark place.

History

The largest amount of cytisine (about 1–5%) is also found in the seeds of common garden decorative plant Du-Dou (Laburnum anagyroides). In the early twentieth century, cytisine was identified as the toxic component of this plant. The extracts of Laburnum seeds or flowers have been used in traditional medicine for hundreds of years. In the Second World War, the leaves of Laburnum anagyroides were used as a tobacco substitute by soldiers. In 1960s, cytisine was firstly used as a smoking cessation aid in Bulgaria. The pharmacological and clinical studies of cytisine were also conducted in other Eastern European countries such as Poland and Russia. These results were promising. Stoyanov S. and Yanachkova M. studied 70 volunteers with a long experience in smoking. They found that 57% volunteers stopped smoking and 31.4% volunteers decreased cigarettes: reduction of the cigarettes smoked from 20–30 to 3–4 a day. Cytisine was developed and marked as Tabex? (Sopharma, Bulgaria), which has been widely distributed in the Eastern Europe .

Uses

Different sources of media describe the Uses of 485-35-8 differently. You can refer to the following data:
1. antiinflammatory, respiratory stimulant
2. Toxic priniciple in seed of Laburnum anagyroides and other Leguminosae. A neuronal nicotinic acetylcholine agonist. Toxic priniciple in seed of Laburnum anagyroides and other Leguminosae. A neuronal nicotinic acetylcholine agonist.
3. Cytisine occurs in the seeds of Cytisus labur num L. and other Leguminosae.

Definition

ChEBI: An organic heterotricyclic compound that is the toxic principle in Laburnum seeds and is found in many members of the Fabaceae (legume, pea or bean) family. An acetylcholine agonist, it is widely used throughout Eastern Europe as n aid to giving up smoking.

Indications

It is the first effective medicine in the world for smoking cessation, which does not contain nicotine and antidepressants. It is administered perorally according to the following schedule:First 3 days: one tablet six times daily (every 2 h) with a parallel reduction of the number of cigarettes smoked.If the result is unsatisfactory, the treatment is discontinued, and a new therapy can be resumed after 2–3 months. In case of good effect, the treatment should continue according to the following schedule:Fourth to 12th day: one tablet every 2 and 1/2 h (five tablets daily)Thirteenth to 16th day: one tablet every 3 h (four tablets daily) Seventeenth to 20th day: one tablet every 5 h (three tablets daily)Twenty-first to 25th day: one to two tablets daily

General Description

Cystine ((1R,5S)-1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-one) displays classical antidepressant action in various animal models of antidepressant efficacy. Infrared and Raman spectral studies suggest that it has two stable conformers.

Health Hazard

Cytisine is highly toxic to humans and ani mals. Ingestions may cause nausea, vomiting,and convulsions. Death may occur from respiratory failureLD50 value, oral (rats): 101 mg/kg.

Biological Activity

A potent, selective agonist at neuronal nicotinic receptors. Acts as a partial agonist at β 2-containing nicotinic receptors.

Biochem/physiol Actions

Potent agonist at α3β4 and α7 nicotinic acetylcholine receptors and partial agonist at α4β2 nicotinic acetylcholine receptors.

Pharmacology

Tobacco smoking is one of the main threats to human health. Nicotine is responsible for the dependence of tobacco, and it is commonly accepted that nicotine addiction results from its interaction with neuronal nicotinic acetylcholine receptors (nAChRs). Cytisine has a similar chemical structure to that of nicotine, and in?vitro binding assays showed that cytisine possesses selective binding affinity for nAChRs, which is superior to that of nicotine and many other nAChR agonists. In vivo studies indicated that cytisine moderately increased the dopamine level in the mesolimbic system and attenuate the withdrawal symptoms.

Clinical Use

Cytisine has been used in the Eastern European countries for many years because of its proven benefits and low cost as compared with other cessation medications. A recent clinical trial in New Zealand found that at 1?month, continuous abstinence from smoking was reported for 40% of participants receiving cytisine (264 of 655) and 31% of participants receiving nicotine replacement therapy (203 of 655) . The available data indicates that cytisine is generally well-tolerated in human. However, high dosages of cytisine can be toxic.

Purification Methods

Crystallise cytisine from acetone and sublime it in a vacuum. Its solubilities are: 77% (H2O), 7.7% (Me2CO), 28.6% (EtOH), 3.3% (*C6H6), 50% (CHCl3) but it is insoluble in pet ether. The tartrate has m 206-207o [] D +45.9o, the N-tosylate has m 206-207o, and the N-acetate has m 208o. [Bohlmann et al. Angew Chem 67 708 1955, van Tamelen & Baran J Am Chem Soc 77 4944 1955, Isolation: Ing J Chem Soc 2200 1931, Govindachari et al. J Chem Soc 3839 1957, Abs config: Okuda et al. Chem Ind (London) 1751 1961, Beilstein 24 H 134, 24 I 244, 24 II 70, 24 III/IV 321.] TOXIC.

Check Digit Verification of cas no

The CAS Registry Mumber 485-35-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,8 and 5 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 485-35:
(5*4)+(4*8)+(3*5)+(2*3)+(1*5)=78
78 % 10 = 8
So 485-35-8 is a valid CAS Registry Number.
InChI:InChI=1/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/p+1/t8-,9+/m0/s1

485-35-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2609)  (-)-Cytisine  >98.0%(GC)(T)

  • 485-35-8

  • 100mg

  • 790.00CNY

  • Detail
  • TCI America

  • (C2609)  (-)-Cytisine  >98.0%(GC)(T)

  • 485-35-8

  • 1g

  • 3,990.00CNY

  • Detail

485-35-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name cytisine

1.2 Other means of identification

Product number -
Other names (-)-Cytisine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:485-35-8 SDS

485-35-8Synthetic route

(6R,7R,9R)-(-)-N-benzyloxycarbonyl-cytisine
667940-15-0

(6R,7R,9R)-(-)-N-benzyloxycarbonyl-cytisine

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran for 3h; Heating;78%
N-nosyl-(−)-cytisine

N-nosyl-(−)-cytisine

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
With potassium carbonate; thiophenol In N,N-dimethyl-formamide; acetonitrile at 45℃; for 0.5h;96%
(1R,9R)-11-tert-butoxycarbonyl-7,11-diazatricyclo[7.3.1.02,7]tridec-2,4-dien-6,10-dione

(1R,9R)-11-tert-butoxycarbonyl-7,11-diazatricyclo[7.3.1.02,7]tridec-2,4-dien-6,10-dione

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Stage #1: (1R,9R)-11-tert-butoxycarbonyl-7,11-diazatricyclo[7.3.1.02,7]tridec-2,4-dien-6,10-dione With methanol; sodium tetrahydroborate at 0 - 20℃; for 2h;
Stage #2: With triethylsilane; boron trifluoride diethyl etherate In dichloromethane at -78 - 20℃; for 15h;
79%
(3S,5R)-(+)-3-acetoxymethyl-5-formyl-1-piperidine-1-carbvoxylic acid benzyl ester
206554-22-5

(3S,5R)-(+)-3-acetoxymethyl-5-formyl-1-piperidine-1-carbvoxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 11 steps
1.1: (-)-B-methoxydiisopinocampheylborane / diethyl ether / 1.25 h / -78 - 20 °C
1.2: diethyl ether / -78 - 20 °C / Acid hydrolysis
1.3: 76 percent / aq. NaOH; aq. H2O2 / 3 h / Heating
2.1: 99 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
3.1: 87 percent / NaN3 / dimethylformamide / 2 h / 80 °C
4.1: Ph3P / tetrahydrofuran
4.2: 66 percent / H2O
5.1: 89 percent / Et3N; DMAP / CH2Cl2 / 4.5 h / 0 - 20 °C
6.1: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
7.1: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
8.1: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
9.1: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
10.1: 50 percent / DDQ / dioxane / 4 h / 110 °C
11.1: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(3S,5R)-3-acetoxymethyl-5-hydroxymethylpiperidine-1-carboxylic acid benzyl ester
206761-38-8

(3S,5R)-3-acetoxymethyl-5-hydroxymethylpiperidine-1-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 12 steps
1.1: (-)-B-methoxydiisopinocampheylborane / diethyl ether / 1.25 h / -78 - 20 °C
1.2: diethyl ether / -78 - 20 °C / Acid hydrolysis
1.3: 76 percent / aq. NaOH; aq. H2O2 / 3 h / Heating
2.1: 99 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
3.1: 87 percent / NaN3 / dimethylformamide / 2 h / 80 °C
4.1: Ph3P / tetrahydrofuran
4.2: 66 percent / H2O
5.1: 89 percent / Et3N; DMAP / CH2Cl2 / 4.5 h / 0 - 20 °C
6.1: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
7.1: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
8.1: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
9.1: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
10.1: 50 percent / DDQ / dioxane / 4 h / 110 °C
11.1: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(3S,5R,1'S)-(-)-3-acetoxymethyl-5-(1'-hydroxybut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester
667940-16-1

(3S,5R,1'S)-(-)-3-acetoxymethyl-5-(1'-hydroxybut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 10 steps
1.1: 99 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
2.1: 87 percent / NaN3 / dimethylformamide / 2 h / 80 °C
3.1: Ph3P / tetrahydrofuran
3.2: 66 percent / H2O
4.1: 89 percent / Et3N; DMAP / CH2Cl2 / 4.5 h / 0 - 20 °C
5.1: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
6.1: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
7.1: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
8.1: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
9.1: 50 percent / DDQ / dioxane / 4 h / 110 °C
10.1: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(3S,5R,1'R)-(-)-3-acetoxymethyl-5-(1'-azidobut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester
667940-11-6

(3S,5R,1'R)-(-)-3-acetoxymethyl-5-(1'-azidobut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: Ph3P / tetrahydrofuran
1.2: 66 percent / H2O
2.1: 89 percent / Et3N; DMAP / CH2Cl2 / 4.5 h / 0 - 20 °C
3.1: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
4.1: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
5.1: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
6.1: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
7.1: 50 percent / DDQ / dioxane / 4 h / 110 °C
8.1: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(3S,5R)-3-Acetoxymethyl-5-((R)-1-amino-but-3-enyl)-piperidine-1-carboxylic acid benzyl ester
667940-18-3

(3S,5R)-3-Acetoxymethyl-5-((R)-1-amino-but-3-enyl)-piperidine-1-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 89 percent / Et3N; DMAP / CH2Cl2 / 4.5 h / 0 - 20 °C
2: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
3: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
4: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
5: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
6: 50 percent / DDQ / dioxane / 4 h / 110 °C
7: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(3S,5R,1'S)-(+)-3-acetoxymethyl-5-(1'-methanesulfonyloxybut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester
667940-10-5

(3S,5R,1'S)-(+)-3-acetoxymethyl-5-(1'-methanesulfonyloxybut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1.1: 87 percent / NaN3 / dimethylformamide / 2 h / 80 °C
2.1: Ph3P / tetrahydrofuran
2.2: 66 percent / H2O
3.1: 89 percent / Et3N; DMAP / CH2Cl2 / 4.5 h / 0 - 20 °C
4.1: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
5.1: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
6.1: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
7.1: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
8.1: 50 percent / DDQ / dioxane / 4 h / 110 °C
9.1: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(3S,5R,1'R)-(+)-3-acetoxymethyl-5-(1'-acryloylaminobut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester
667940-08-1

(3S,5R,1'R)-(+)-3-acetoxymethyl-5-(1'-acryloylaminobut-3'-enyl)-1-piperidine-1-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 79 percent / Cl2Ru(CHPh)(PCy3)2 / CH2Cl2 / 12 h / Heating
2: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
3: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
4: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
5: 50 percent / DDQ / dioxane / 4 h / 110 °C
6: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one
485-35-8, 15191-27-2, 55821-72-2

1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
With camphor-10-sulfonic acid
(6R,7R,9R)-(+)-N-benzyloxycarbonyl-5,6-dihydro-cytisine
667940-14-9

(6R,7R,9R)-(+)-N-benzyloxycarbonyl-5,6-dihydro-cytisine

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 50 percent / DDQ / dioxane / 4 h / 110 °C
2: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(2R,3'R,5'S)-(+)-5-hydroxymethyl-6-oxo-1,2,3,6,3',4',5',6'-octahydro-2'H-[2,3']-bipyridinyl-1'-carboxylic acid benzyl ester
667940-12-7

(2R,3'R,5'S)-(+)-5-hydroxymethyl-6-oxo-1,2,3,6,3',4',5',6'-octahydro-2'H-[2,3']-bipyridinyl-1'-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
2: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
3: 50 percent / DDQ / dioxane / 4 h / 110 °C
4: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(2R,3'R,5'S)-(+)-5-acetoxymethyl-6-oxo-1,2,3,6,3',4',5',6'-octahydro-2'H-[2,3']-bipyridinyl-1'-carboxylic acid benzyl ester
667940-07-0

(2R,3'R,5'S)-(+)-5-acetoxymethyl-6-oxo-1,2,3,6,3',4',5',6'-octahydro-2'H-[2,3']-bipyridinyl-1'-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 98 percent / NaOH / tetrahydrofuran / 2 h / 20 °C
2: 67 percent / Et3N; DMAP / CH2Cl2 / 1.5 h / 20 °C
3: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
4: 50 percent / DDQ / dioxane / 4 h / 110 °C
5: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(2R,3'R,5'S)-(+)-5-methanesulfonyloxymethyl-6-oxo-1,2,3,6,3',4',5',6'-octahydro-2'H-[2,3']-bipyridinyl-1'-carboxylic acid benzyl ester
667940-13-8

(2R,3'R,5'S)-(+)-5-methanesulfonyloxymethyl-6-oxo-1,2,3,6,3',4',5',6'-octahydro-2'H-[2,3']-bipyridinyl-1'-carboxylic acid benzyl ester

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 89 percent / NaH / tetrahydrofuran / 0 - 20 °C
2: 50 percent / DDQ / dioxane / 4 h / 110 °C
3: 78 percent / HCl / tetrahydrofuran / 3 h / Heating
View Scheme
(1R,5R)-6-methyl-3,7-diazabicyclo[3.3.1]non-6-en-2-one

(1R,5R)-6-methyl-3,7-diazabicyclo[3.3.1]non-6-en-2-one

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: triethylamine; dmap / dichloromethane / 20 h
2.1: triethylamine / tetrahydrofuran / 5 h / 20 °C
3.1: methanol; sodium tetrahydroborate / 2 h / 0 - 20 °C
3.2: 15 h / -78 - 20 °C
View Scheme
(1R,5R)-3-tert-butoxycarbonyl-6-methyl-3,7-diazabicyclo[3.3.1]non-6-en-2-one

(1R,5R)-3-tert-butoxycarbonyl-6-methyl-3,7-diazabicyclo[3.3.1]non-6-en-2-one

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: triethylamine / tetrahydrofuran / 5 h / 20 °C
2.1: methanol; sodium tetrahydroborate / 2 h / 0 - 20 °C
2.2: 15 h / -78 - 20 °C
View Scheme
methyl 5-(6-bromopyridin-2-yl)-1-tosylpiperidine-3-carboxylate

methyl 5-(6-bromopyridin-2-yl)-1-tosylpiperidine-3-carboxylate

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: lithium aluminium tetrahydride / tetrahydrofuran / 0 °C
2.1: triethylamine / dichloromethane / 1 h / 0 °C
3.1: chloroform / 6.5 h / Reflux
3.2: 9 h / 23 °C
4.1: thiophenol; potassium carbonate / acetonitrile; N,N-dimethyl-formamide / 0.5 h / 45 °C
View Scheme
(5-(6-bromopyridin-2-yl)-1-tosylpiperidin-3-yl)methanol

(5-(6-bromopyridin-2-yl)-1-tosylpiperidin-3-yl)methanol

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: triethylamine / dichloromethane / 1 h / 0 °C
2.1: chloroform / 6.5 h / Reflux
2.2: 9 h / 23 °C
3.1: thiophenol; potassium carbonate / acetonitrile; N,N-dimethyl-formamide / 0.5 h / 45 °C
View Scheme
C19H23BrN2O5S2

C19H23BrN2O5S2

cytisine
485-35-8

cytisine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: chloroform / 6.5 h / Reflux
1.2: 9 h / 23 °C
2.1: thiophenol; potassium carbonate / acetonitrile; N,N-dimethyl-formamide / 0.5 h / 45 °C
View Scheme
cytisine
485-35-8

cytisine

Nitrosocytisine
19634-60-7

Nitrosocytisine

Conditions
ConditionsYield
With hydrogenchloride; sodium nitrite at 20℃; for 288h; Nitrosation;100%
With potassiuim nitrosodisulfonate; hydroxylamine hydrochloride; sodium carbonate In pyridine for 0.25h;91%
acetic anhydride
108-24-7

acetic anhydride

cytisine
485-35-8

cytisine

(-)-(1R,5S)-N-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido-[1,2-a][1,5]diazocin-8-one
6018-52-6

(-)-(1R,5S)-N-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido-[1,2-a][1,5]diazocin-8-one

Conditions
ConditionsYield
With dmap In pyridine at 20℃; for 12h; Acetylation;100%
88.4%
1-adamantyl isocyanate
4411-25-0

1-adamantyl isocyanate

cytisine
485-35-8

cytisine

N-1-adamantylcytisine-12-carbamide

N-1-adamantylcytisine-12-carbamide

Conditions
ConditionsYield
In benzene at 80℃;100%
1-adamantylisothiocyanate
4411-26-1

1-adamantylisothiocyanate

cytisine
485-35-8

cytisine

N-1-adamantylcytisine-12-thiocarbamide
1621257-20-2

N-1-adamantylcytisine-12-thiocarbamide

Conditions
ConditionsYield
In benzene at 80℃;100%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

cytisine
485-35-8

cytisine

8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carboxylic acid tert-butyl ester [N-tboccytisine]
207390-62-3

8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocine-3-carboxylic acid tert-butyl ester [N-tboccytisine]

Conditions
ConditionsYield
With sodium carbonate In tetrahydrofuran; water at 20℃; for 48h;99%
With sodium carbonate In tetrahydrofuran at 20℃; for 24h;96%
With sodium carbonate In tetrahydrofuran; water for 72h;93%
benzyl bromide
100-39-0

benzyl bromide

cytisine
485-35-8

cytisine

(1R,9S)-11-benzyl-7,11-diazatricyclo[7.3.1.0]trideca-2,4-dien-6-one
78867-61-5, 109667-42-7

(1R,9S)-11-benzyl-7,11-diazatricyclo[7.3.1.0]trideca-2,4-dien-6-one

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 20h; Reflux;99%
With potassium carbonate In acetonitrile for 5h; Heating;94%
With potassium carbonate In acetonitrile for 5h; Reflux; Inert atmosphere;94%
With sodium carbonate In dichloromethane; water for 4h; Heating;77%
thiourea
17356-08-0

thiourea

cytisine
485-35-8

cytisine

N-cytisine-12-thiocarbamide
1401073-44-6

N-cytisine-12-thiocarbamide

Conditions
ConditionsYield
In pentan-1-ol at 137℃;98%
allylisocyanate
1476-23-9

allylisocyanate

cytisine
485-35-8

cytisine

N-allylcytisine-11-carbamide
449797-68-6

N-allylcytisine-11-carbamide

Conditions
ConditionsYield
In benzene at 20℃;98%
phenyl isocyanate
103-71-9

phenyl isocyanate

cytisine
485-35-8

cytisine

N-phenylcytisine-11-carbamide
40705-13-3

N-phenylcytisine-11-carbamide

Conditions
ConditionsYield
In benzene at 20℃;98%
di(4-isocyanatophenyl)methane
101-68-8

di(4-isocyanatophenyl)methane

cytisine
485-35-8

cytisine

N,N'-[methylene-bis(4,1-phenylene)]dicytisinecarboxamide
1620659-65-5

N,N'-[methylene-bis(4,1-phenylene)]dicytisinecarboxamide

Conditions
ConditionsYield
In benzene at 80℃;98%
2-(4-phenoxybutyl)oxirane
85234-59-9

2-(4-phenoxybutyl)oxirane

cytisine
485-35-8

cytisine

(1R,2'ζ,5S)-3-(2-hydroxy-6-phenoxyhexyl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

(1R,2'ζ,5S)-3-(2-hydroxy-6-phenoxyhexyl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

Conditions
ConditionsYield
In methanol at 90℃; for 8h;98%
formaldehyd
50-00-0

formaldehyd

Ethyl isocyanoacetate
2999-46-4

Ethyl isocyanoacetate

cytisine
485-35-8

cytisine

ethyl 2-(5-(((1R,5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)methyl)-1H-tetrazol-1-yl)acetate

ethyl 2-(5-(((1R,5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)methyl)-1H-tetrazol-1-yl)acetate

Conditions
ConditionsYield
With trimethylsilylazide In methanol at 20℃; for 24h; Ugi Condensation;98%
formaldehyd
50-00-0

formaldehyd

cytisine
485-35-8

cytisine

methyl 3-isocyanopropanoate

methyl 3-isocyanopropanoate

methyl 3-(5-(((1R,5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)methyl)-1H-tetrazol-1-yl)propanoate

methyl 3-(5-(((1R,5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)methyl)-1H-tetrazol-1-yl)propanoate

Conditions
ConditionsYield
With trimethylsilylazide In methanol at 20℃; for 24h; Ugi Condensation;98%
Methoxyacetyl chloride
38870-89-2

Methoxyacetyl chloride

cytisine
485-35-8

cytisine

(1R,5S)-N-(2-methoxyacetyl)-1,2,3,4,5,6-hexahydro-1,5-methanopyrido[1,2-a]diazocin-8-one
881853-39-0

(1R,5S)-N-(2-methoxyacetyl)-1,2,3,4,5,6-hexahydro-1,5-methanopyrido[1,2-a]diazocin-8-one

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0 - 20℃; for 18h;97%
3,5-dichlorobenzoyl chloride
2905-62-6

3,5-dichlorobenzoyl chloride

cytisine
485-35-8

cytisine

(1R,5S)-3-(3,5-Dichloro-benzoyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one

(1R,5S)-3-(3,5-Dichloro-benzoyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one

Conditions
ConditionsYield
With triethylamine In acetone Acylation; Heating;96%
propionyl chloride
79-03-8

propionyl chloride

cytisine
485-35-8

cytisine

(1R,5S)-3-propionyl-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one
474116-07-9

(1R,5S)-3-propionyl-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃;96%
With triethylamine In dichloromethane at 0 - 22℃; for 3h;12.3 g
N-allyl isothiocyanate
57-06-7

N-allyl isothiocyanate

cytisine
485-35-8

cytisine

cytisino-N-allylthiocarbamide
945421-04-5

cytisino-N-allylthiocarbamide

Conditions
ConditionsYield
In benzene at 35 - 40℃;96%
1,1-bis(diethylphosphono)ethylene
37465-31-9

1,1-bis(diethylphosphono)ethylene

cytisine
485-35-8

cytisine

C13H20N2O7P2*BrH

C13H20N2O7P2*BrH

Conditions
ConditionsYield
In chloroform at 20℃; for 72h;96%
3-(4-chlorophenyl)-2-methyl-7-(4-(oxiran-2-yl)butoxy)-4H-chromen-4-one

3-(4-chlorophenyl)-2-methyl-7-(4-(oxiran-2-yl)butoxy)-4H-chromen-4-one

cytisine
485-35-8

cytisine

(1R,2’ζ,5S)-3-(6-((3-(4-chlorophenyl)-2-methyl-4-oxo-4H-chromen-7-yl)oxy)-2-hydroxyhexyl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

(1R,2’ζ,5S)-3-(6-((3-(4-chlorophenyl)-2-methyl-4-oxo-4H-chromen-7-yl)oxy)-2-hydroxyhexyl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

Conditions
ConditionsYield
In ethanol at 90℃; for 20h;96%
In ethanol at 90℃; for 20h;96%
cytisine
485-35-8

cytisine

formic acid ethyl ester
109-94-4

formic acid ethyl ester

(1R,5S)-8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido[1,2-a][1,5]diazocine-3(4H)-carbaldehyde
53007-06-0

(1R,5S)-8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido[1,2-a][1,5]diazocine-3(4H)-carbaldehyde

Conditions
ConditionsYield
With triethylamine for 19h; Reflux;96%
tert-butylisonitrile
119072-55-8, 7188-38-7

tert-butylisonitrile

pentan-3-one
96-22-0

pentan-3-one

cytisine
485-35-8

cytisine

(1R,5S)-3-(3-(1-(tert-butyl)-1H-tetrazol-5-yl)pentan-3-yl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

(1R,5S)-3-(3-(1-(tert-butyl)-1H-tetrazol-5-yl)pentan-3-yl)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one

Conditions
ConditionsYield
With trimethylsilylazide In methanol at 20℃; for 24h; Ugi Condensation;96%

485-35-8Upstream product

485-35-8Relevant articles and documents

Synthesis of (-)-Cytisine Using a 6- endo aza-Michael Addition

Barát, Viktor,Csókás, Dániel,Bates, Roderick W.

, p. 9088 - 9095 (2018/07/25)

An asymmetric synthesis of (-)-cytisine has been achieved. The piperidine C-ring was formed using a stereodivergent intramolecular 6-endo aza-Michael addition. The B-ring was established by intramolecular pyridine N-alkylation. The absolute stereochemistry was established by an Evans acyl oxazolidinone enolate alkylation reaction that proceeded with an unexpected stereochemical outcome due to participation of the pyridine nitrogen lone pair.

Concise synthesis of (±)-cytisine via lithiation of N-Boc-bispidine

Stead, Darren,O'Brien, Peter,Sanderson, Adam J.

, p. 4459 - 4462 (2007/10/03)

(Chemical Equation Presented) (±)-Cytisine has been synthesized in 19% overall yield via a six-step approach from commercially available materials. Key features of this new strategy are as follows: (i) initial construction of the bispidine core, (ii) lithiation-transmetalation-allylation of an N-Boc-bispidine, and (iii) a Pd/C-mediated dihydropyridone oxidation-N- debenzylation process.

Total synthesis of (+/-)-cytisine via the intramolecular heck cyclization of activated N-alkyl glutarimides.

Coe

, p. 4205 - 4208 (2007/10/03)

[reaction:see text] A synthesis of racemic cytisine 1 has been developed utilizing an intramolecular Heck cyclization to prepare the bridged tricyclic intermediate 2. The cyclization employs activated glutarimide-derived ketene aminals 3 (X = P(O)OEt(2) or SO(2)CF(3)) and represents the first use of such intermediates in metal-catalyzed processes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 485-35-8